<DOC>
	<DOCNO>NCT01587079</DOCNO>
	<brief_summary>The primary objective study assess efficacy Glycopyrrolate/Formoterol Fumarate MDI relative individual component ( GP MDI FF MDI ) subject moderate severe COPD</brief_summary>
	<brief_title>Glycopyrrolate/Formoterol Fumarate MDI Compared With SpirivaÂ® An Active Control Patients With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Key Signed write informed consent 40 80 year age Clinical history COPD airflow limitation fully reversible Females nonchild bear potential female child bear potential negative pregnancy test acceptable contraceptive method Current/former smoker least 10 packyear history cigarette smoke A measured postbronchodilator FEV1/FVC ratio &lt; = 0.70 A measured postbronchodilator FEV1 &gt; = 750ml 30 % predict &lt; = 80 % predict normal value Able change COPD treatment require protocol Key Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray due presence COPD Hospitalized due poorly control COPD within 3 month Screening Clinically significant medical condition preclude participation study ( e.g . clinically significant abnormal ECG , uncontrolled hypertension , glaucoma , symptomatic prostatic hypertrophy ) Cancer complete remission least 5 year Treatment investigational study drug participation another clinical trial study within last 30 day 5 half live Other inclusion/exclusion criterion define protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>